Lyell Immunopharma Files 8-K for Other Event
Ticker: LYEL · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-event
TL;DR
Lyell Immunopharma filed an 8-K for an 'Other Event' on Dec 7th. Details TBD.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on December 8, 2025, reporting an "Other Event" that occurred on December 7, 2025. The filing does not provide specific details about the event itself, only that it is being reported under Item 8.01.
Why It Matters
This filing indicates a material event has occurred for Lyell Immunopharma, Inc. that requires disclosure to the public, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is a standard 8-K for an 'Other Event' which could be significant, but the lack of detail necessitates a medium risk assessment until more information is available.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- December 7, 2025 (date) — Date of earliest event reported
- December 8, 2025 (date) — Date of Report
FAQ
What specific event is Lyell Immunopharma, Inc. reporting under Item 8.01?
The filing does not specify the nature of the 'Other Event' reported on December 7, 2025.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on December 8, 2025.
What is the principal executive office address for Lyell Immunopharma, Inc.?
The address is 201 Haskins Way, South San Francisco, California, 94080.
What is Lyell Immunopharma, Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number is 83-1300510.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,113 words · 4 min read · ~4 pages · Grade level 15.2 · Accepted 2025-12-08 06:02:14
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq
Filing Documents
- d35459d8k.htm (8-K) — 33KB
- 0001193125-25-310469.txt ( ) — 142KB
- lyel-20251207.xsd (EX-101.SCH) — 3KB
- lyel-20251207_lab.xml (EX-101.LAB) — 17KB
- lyel-20251207_pre.xml (EX-101.PRE) — 11KB
- d35459d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: December 8, 2025 By: /s/ Mark Meltz Mark Meltz General Counsel